Peer-reviewedCC BY-NCEBioMedicine
Engineering clinically actionable nanomedicine for cancer immunometabolic ecosystem reprogramming
Related
- Pan-cancer analysis identifies nine conserved miRNA regulators of tumor cytolytic activity and clinically actionable immune targets
- Why Circulating Interleukin‐6 Is Not Yet a Standalone Clinically Actionable Biomarker in HFrEF: A Context‐of‐Use Review
- Clinically Actionable Prevention and Management of Major Complications During Durable Left Ventricular Assist Device Support: A Contemporary Narrative Review
- Predicting clinically actionable metagenomic next-generation sequencing in sepsis through dynamic inflammatory trajectories
- ApoE lipidation state directs immunometabolic reprogramming of human microglia
BibTeX
@article{gao2026engineering,
title = {{Engineering clinically actionable nanomedicine for cancer immunometabolic ecosystem reprogramming}},
author = {Yuhong Gao and Xiulin Dong and Sijia Hua and Lingyun Li and Xiaofeng Zhang and Jianfeng Yang},
journal = {EBioMedicine},
year = {2026},
month = oct,
doi = {10.1016/j.ebiom.2026.106501},
url = {https://europepmc.org/article/PMC/PMC13673106},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Engineering clinically actionable nanomedicine for cancer immunometabolic ecosystem reprogramming
AU - Yuhong Gao
AU - Xiulin Dong
AU - Sijia Hua
AU - Lingyun Li
AU - Xiaofeng Zhang
AU - Jianfeng Yang
PY - 2026
DA - 2026/10/01
JO - EBioMedicine
DO - 10.1016/j.ebiom.2026.106501
UR - https://europepmc.org/article/PMC/PMC13673106
SN - 2352-3964
ER -